Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wolff

Showing results (751-760 of 831) with videos related to

Pageof 84
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2019
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without ChemotherapyCarmine De Angelis, Chandandeep Nagi, Cliff C Hoyt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerJ Veeraraghavan, C De Angelis, R Mao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2024
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast CancerBryan P Schneider, Fengmin Zhao, Tarah J Ballinger, et al.
Breast Cancer Research and Treatment|July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Research Square|May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Breast Cancer Research and Treatment|July 9, 2014
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastasesCarey Anders, Allison M Deal, Vandana Abramson, et al.
ACS Omega|September 29, 2025
Screening of Medicines for Malaria Venture Open Boxes Identifies Potent SARS-CoV‑2 Papain-like Protease (PL<sup>pro</sup>) InhibitorsVictor Oliveira Gawriljuk, Gabriela Dias Noske, Rafaela Sachetto Fernandes, et al.
Radiology|August 3, 2021
Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial)Shinn-Huey S Chou, Justin Romanoff, Constance D Lehman, et al.
Breast (Edinburgh, Scotland)|March 6, 2025
A composite <sup>18</sup>F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
Radiology|September 20, 2021
Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial)Shinn-Huey S Chou, Justin Romanoff, Constance D Lehman, et al.
Pageof 84

Showing results (751-760 of 831) with videos related to

Sort By:
Pageof 84
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2019
Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without ChemotherapyCarmine De Angelis, Chandandeep Nagi, Cliff C Hoyt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 24, 2019
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancerJ Veeraraghavan, C De Angelis, R Mao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2024
ECOG-ACRIN EAZ171: Prospective Validation Trial of Germline Predictors of Taxane-Induced Peripheral Neuropathy in Black Women With Early-Stage Breast CancerBryan P Schneider, Fengmin Zhao, Tarah J Ballinger, et al.
Breast Cancer Research and Treatment|July 5, 2024
A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Research Square|May 15, 2024
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)Jessica Mezzanotte-Sharpe, Anne ONeill, Ingrid A Mayer, et al.
Breast Cancer Research and Treatment|July 9, 2014
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastasesCarey Anders, Allison M Deal, Vandana Abramson, et al.
ACS Omega|September 29, 2025
Screening of Medicines for Malaria Venture Open Boxes Identifies Potent SARS-CoV‑2 Papain-like Protease (PL<sup>pro</sup>) InhibitorsVictor Oliveira Gawriljuk, Gabriela Dias Noske, Rafaela Sachetto Fernandes, et al.
Radiology|August 3, 2021
Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial)Shinn-Huey S Chou, Justin Romanoff, Constance D Lehman, et al.
Breast (Edinburgh, Scotland)|March 6, 2025
A composite <sup>18</sup>F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
Radiology|September 20, 2021
Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial)Shinn-Huey S Chou, Justin Romanoff, Constance D Lehman, et al.
Pageof 84